Floatz logo

Tazarotene

Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

McGill UniversitySmall moleculePhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

59 Active assets in the Primary Cutaneous T-Cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
(+)-Vincristine
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Cyclophosphamide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Bexarotene
Case Comprehensive Cancer Center
Phase 4BBB
Dexasone
National Cancer Institute (NCI)
Phase 2BBB
Fludarabine
National Cancer Institute (NCI)
Phase 2BBB

View all 50 →

Same molecule, other indications

Tazarotene is also rated in:

idiopathic pulmonary fibrosisActive
CCC
Indicative · Phase 2
54 / 100
View asset →
hand-foot syndromeDormant
CCC
Indicative · Phase 2
53 / 100
View asset →
neoplasmDormant
CC
Indicative · Phase 2
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →